

Market Analysis and Insights: Global Afatinib Market
The global Afatinib market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Afatinib is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Afatinib is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The Europe market for Afatinib is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The global key companies of Afatinib include Boehringer Ingelheim, Hengrui Medicine and Beacon Pharma, etc. In 2023, the global top five players had a share approximately % in terms of revenue.
Afatinib is widely used in various fields, such as Hospital, Clinic, Drug Center and Others, etc. Hospital provides greatest supports to the Afatinib industry development. In 2023, global % revenue of Afatinib went into Hospital filed and the proportion will reach to % in 2030.
Report Covers:
This report presents an overview of global market for Afatinib market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Afatinib, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Afatinib, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Afatinib revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Afatinib market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Afatinib revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Boehringer Ingelheim
Hengrui Medicine
Beacon Pharma
Segment by Type
30mg Tables
40mg Tables
50mg Tables
25mg Tables
20mg Tables
Others
Segment by Application
Hospital
Clinic
Drug Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Afatinib in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Afatinib companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Afatinib revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Afatinib Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 30mg Tables
1.2.3 40mg Tables
1.2.4 50mg Tables
1.2.5 25mg Tables
1.2.6 20mg Tables
1.2.7 Others
1.3 Market by Application
1.3.1 Global Afatinib Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Afatinib Market Perspective (2019-2030)
2.2 Global Afatinib Growth Trends by Region
2.2.1 Afatinib Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Afatinib Historic Market Size by Region (2019-2024)
2.2.3 Afatinib Forecasted Market Size by Region (2025-2030)
2.3 Afatinib Market Dynamics
2.3.1 Afatinib Industry Trends
2.3.2 Afatinib Market Drivers
2.3.3 Afatinib Market Challenges
2.3.4 Afatinib Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Afatinib by Players
3.1.1 Global Afatinib Revenue by Players (2019-2024)
3.1.2 Global Afatinib Revenue Market Share by Players (2019-2024)
3.2 Global Afatinib Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Afatinib, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Afatinib Market Concentration Ratio
3.4.1 Global Afatinib Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Afatinib Revenue in 2023
3.5 Global Key Players of Afatinib Head office and Area Served
3.6 Global Key Players of Afatinib, Product and Application
3.7 Global Key Players of Afatinib, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Afatinib Breakdown Data by Type
4.1 Global Afatinib Historic Market Size by Type (2019-2024)
4.2 Global Afatinib Forecasted Market Size by Type (2025-2030)
5 Afatinib Breakdown Data by Application
5.1 Global Afatinib Historic Market Size by Application (2019-2024)
5.2 Global Afatinib Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Afatinib Market Size (2019-2030)
6.2 North America Afatinib Market Size by Type
6.2.1 North America Afatinib Market Size by Type (2019-2024)
6.2.2 North America Afatinib Market Size by Type (2025-2030)
6.2.3 North America Afatinib Market Share by Type (2019-2030)
6.3 North America Afatinib Market Size by Application
6.3.1 North America Afatinib Market Size by Application (2019-2024)
6.3.2 North America Afatinib Market Size by Application (2025-2030)
6.3.3 North America Afatinib Market Share by Application (2019-2030)
6.4 North America Afatinib Market Size by Country
6.4.1 North America Afatinib Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Afatinib Market Size by Country (2019-2024)
6.4.3 North America Afatinib Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Afatinib Market Size (2019-2030)
7.2 Europe Afatinib Market Size by Type
7.2.1 Europe Afatinib Market Size by Type (2019-2024)
7.2.2 Europe Afatinib Market Size by Type (2025-2030)
7.2.3 Europe Afatinib Market Share by Type (2019-2030)
7.3 Europe Afatinib Market Size by Application
7.3.1 Europe Afatinib Market Size by Application (2019-2024)
7.3.2 Europe Afatinib Market Size by Application (2025-2030)
7.3.3 Europe Afatinib Market Share by Application (2019-2030)
7.4 Europe Afatinib Market Size by Country
7.4.1 Europe Afatinib Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Afatinib Market Size by Country (2019-2024)
7.4.3 Europe Afatinib Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Afatinib Market Size (2019-2030)
8.2 China Afatinib Market Size by Type
8.2.1 China Afatinib Market Size by Type (2019-2024)
8.2.2 China Afatinib Market Size by Type (2025-2030)
8.2.3 China Afatinib Market Share by Type (2019-2030)
8.3 China Afatinib Market Size by Application
8.3.1 China Afatinib Market Size by Application (2019-2024)
8.3.2 China Afatinib Market Size by Application (2025-2030)
8.3.3 China Afatinib Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Afatinib Market Size (2019-2030)
9.2 Asia Afatinib Market Size by Type
9.2.1 Asia Afatinib Market Size by Type (2019-2024)
9.2.2 Asia Afatinib Market Size by Type (2025-2030)
9.2.3 Asia Afatinib Market Share by Type (2019-2030)
9.3 Asia Afatinib Market Size by Application
9.3.1 Asia Afatinib Market Size by Application (2019-2024)
9.3.2 Asia Afatinib Market Size by Application (2025-2030)
9.3.3 Asia Afatinib Market Share by Application (2019-2030)
9.4 Asia Afatinib Market Size by Region
9.4.1 Asia Afatinib Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Afatinib Market Size by Region (2019-2024)
9.4.3 Asia Afatinib Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Afatinib Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Afatinib Market Size by Type
10.2.1 Middle East, Africa, and Latin America Afatinib Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Afatinib Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Afatinib Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Afatinib Market Size by Application
10.3.1 Middle East, Africa, and Latin America Afatinib Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Afatinib Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Afatinib Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Afatinib Market Size by Country
10.4.1 Middle East, Africa, and Latin America Afatinib Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Afatinib Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Afatinib Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Details
11.1.2 Boehringer Ingelheim Business Overview
11.1.3 Boehringer Ingelheim Afatinib Introduction
11.1.4 Boehringer Ingelheim Revenue in Afatinib Business (2019-2024)
11.1.5 Boehringer Ingelheim Recent Developments
11.2 Hengrui Medicine
11.2.1 Hengrui Medicine Company Details
11.2.2 Hengrui Medicine Business Overview
11.2.3 Hengrui Medicine Afatinib Introduction
11.2.4 Hengrui Medicine Revenue in Afatinib Business (2019-2024)
11.2.5 Hengrui Medicine Recent Developments
11.3 Beacon Pharma
11.3.1 Beacon Pharma Company Details
11.3.2 Beacon Pharma Business Overview
11.3.3 Beacon Pharma Afatinib Introduction
11.3.4 Beacon Pharma Revenue in Afatinib Business (2019-2024)
11.3.5 Beacon Pharma Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Boehringer Ingelheim
Hengrui Medicine
Beacon Pharma
Ìý
Ìý
*If Applicable.